A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...

GLP-1 drugs also improve blood flow to the heart ... and therefore a positive effect in Alzheimer’s disease and Parkinson’s disease,” note the authors. More than 100 preclinical research ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

Clinical trials of GLP-1 drugs have found they can lower inflammation, decrease the risk of cardiovascular and kidney disease and may ... as Alzheimer’s and Parkinson’s. If you are considering ...

GLP-1 drugs also improve blood flow to the heart and act directly ... memory formation and therefore a positive effect in Alzheimer’s disease and Parkinson’s disease,” note the authors. More than 100 ...